- Home
- TWIN vs ATOS Comparison
TWIN vs ATOS Comparison
Compare TWIN & ATOS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TWIN
- ATOS
- Stock Information
- Founded
- TWIN 1918
- ATOS 2009
- Country
- TWIN United States
- ATOS United States
- Employees
- TWIN N/A
- ATOS N/A
- Industry
- TWIN Industrial Machinery/Components
- ATOS Biotechnology: Pharmaceutical Preparations
- Sector
- TWIN Industrials
- ATOS Health Care
- Exchange
- TWIN Nasdaq
- ATOS Nasdaq
- Market Cap
- TWIN 97.0M
- ATOS 112.5M
- IPO Year
- TWIN N/A
- ATOS 2012
- Fundamental
- Price
- TWIN $7.79
- ATOS $0.79
- Analyst Decision
- TWIN Strong Buy
- ATOS Strong Buy
- Analyst Count
- TWIN 1
- ATOS 3
- Target Price
- TWIN $12.00
- ATOS $6.17
- AVG Volume (30 Days)
- TWIN 63.7K
- ATOS 656.4K
- Earning Date
- TWIN 08-14-2025
- ATOS 08-11-2025
- Dividend Yield
- TWIN 1.94%
- ATOS N/A
- EPS Growth
- TWIN N/A
- ATOS N/A
- EPS
- TWIN 0.29
- ATOS N/A
- Revenue
- TWIN $328,478,000.00
- ATOS N/A
- Revenue This Year
- TWIN $27.91
- ATOS N/A
- Revenue Next Year
- TWIN N/A
- ATOS N/A
- P/E Ratio
- TWIN $28.29
- ATOS N/A
- Revenue Growth
- TWIN 11.49
- ATOS N/A
- 52 Week Low
- TWIN $6.16
- ATOS $0.55
- 52 Week High
- TWIN $14.98
- ATOS $1.66
- Technical
- Relative Strength Index (RSI)
- TWIN 65.02
- ATOS 44.68
- Support Level
- TWIN $7.43
- ATOS $0.80
- Resistance Level
- TWIN $8.23
- ATOS $0.86
- Average True Range (ATR)
- TWIN 0.29
- ATOS 0.05
- MACD
- TWIN 0.06
- ATOS -0.01
- Stochastic Oscillator
- TWIN 94.87
- ATOS 17.33
About TWIN Twin Disc Incorporated
Twin Disc Inc is a United States-based firm engaged in the manufacture and sale of marine and heavy-duty off-highway power transmission equipment. The company operates its business through two reportable segments: Manufacturing and Distribution. Its product portfolio includes marine transmissions, surface drives, propellers, and boat management systems as well as power-shift transmissions, hydraulic torque converters, power take-offs, industrial clutches, and control systems.
About ATOS Atossa Therapeutics Inc.
Atossa Therapeutics Inc is a clinical stage biopharmaceutical company developing proprietary medicines in areas of unmet medical need in oncology. It focuses on the development of novel therapeutics and delivery methods for the treatment of breast cancer, other breast conditions and COVID-19. The company's drug under development for breast cancer and other breast conditions is Endoxifen. Its two COVID-19 drugs under development are AT-H201, to improve lung function of moderate to severely ill, hospitalized COVID-19 patients by inhalation; and AT-301, a nasal spray for COVID-19 patients for at-home use.